StockData

Longeveron vs ProKidney

LGVN and PROK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How LGVN and PROK compare

ProKidney is the larger company, worth 4.9 times as much as Longeveron ($333M against $67.3M).

ProKidney grew revenue faster over the last twelve months (55.2% versus −42.7% for Longeveron).

Longeveron keeps more of each dollar of sales as profit, with a net margin of −1978% compared with −10288% at ProKidney.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricLGVNPROK
Size and price
Market cap$67.3M$333M
Share price$2.11$1.10
Change, 1 year−69.0%−54.4%
Change, 5 years−99.9%−88.9%
Beta (5Y)1.441.93
Employees37231
StockData Score
Total score55
Valuation score00
Growth score01 (better)
Performance score00
Health score5 (better)4
Dividend score00
Valuation
P/S56.7× (better)407×
P/B6.5×–
FCF yield−30.5% (better)−48.0%
Growth
Revenue growth (TTM)−42.7%55.2% (better)
Revenue growth, 5Y average−26.6%–
Profitability
Gross margin69.8%–
Operating margin−1993% (better)−21665%
Net margin−1978% (better)−10288%
FCF margin−1730% (better)−19527%
Return on equity−204%–
Return on invested capital−1412%–
Financial health
Debt / equity0.00–
Interest coverage–−9327.2×
Current ratio2.638.36 (better)
Altman Z-score−9.42−1.33 (better)
Piotroski F-score12 (better)
Dividends and buybacks
Buyback yield–−7.3%
Shareholder yield0.00% (better)−7.3%
Ownership
Held by institutions1.5%16.1%
Held by insiders43.8%62.9%
Insider net buying, 12 months–−$1.1M
Short interest, % of float0.88%21.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.